Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Triple-Negative Breast Cancer”

158 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 158 results

Large-scale testing (Phase 3)Active Not RecruitingNCT06519370
What this trial is testing

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 350
Large-scale testing (Phase 3)Study completedNCT04085276
What this trial is testing

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Who this might be right for
Triple-Negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd. 531
Testing effectiveness (Phase 2)Ended earlyNCT01147016
What this trial is testing

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Who this might be right for
Breast Cancer
Barbara Ann Karmanos Cancer Institute 8
Testing effectiveness (Phase 2)Looking for participantsNCT06471205
What this trial is testing

BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT02484404
What this trial is testing

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Who this might be right for
Colorectal NeoplasmsBreast Neoplasms
National Cancer Institute (NCI) 268
Testing effectiveness (Phase 2)Study completedNCT00733408
What this trial is testing

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerProgesterone Receptor-negative Breast Cancer+3 more
University of Washington 59
Early research (Phase 1)Ended earlyNCT03861403
What this trial is testing

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced Triple Negative Breast CancerAdvanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer+2 more
Leap Therapeutics, Inc. 10
Early research (Phase 1)Ended earlyNCT01876251
What this trial is testing

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Pfizer 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03616886
What this trial is testing

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

Who this might be right for
Triple Negative Breast Cancer
Jules Bordet Institute 129
Early research (Phase 1)Looking for participantsNCT06465069
What this trial is testing

LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Who this might be right for
Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid Tumor+11 more
Eli Lilly and Company 420
Testing effectiveness (Phase 2)Looking for participantsNCT05464082
What this trial is testing

Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC

Who this might be right for
Breast Cancer Recurrent
University of Utah 80
Testing effectiveness (Phase 2)Study completedNCT00448305
What this trial is testing

EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

Who this might be right for
Breast Neoplasms
MediGene 143
Testing effectiveness (Phase 2)WithdrawnNCT01612910
What this trial is testing

Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery

Who this might be right for
Breast Cancer Female
Barbara Ann Karmanos Cancer Institute
Large-scale testing (Phase 3)Looking for participantsNCT07533123
What this trial is testing

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Who this might be right for
Triple Negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 364
Testing effectiveness (Phase 2)Ended earlyNCT02624700
What this trial is testing

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerRecurrent Breast Cancer
Virginia Commonwealth University 13
Large-scale testing (Phase 3)Study completedNCT01881230
What this trial is testing

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

Who this might be right for
Breast TumorBreast CancerCancer of the Breast+8 more
Celgene 191
Testing effectiveness (Phase 2)Looking for participantsNCT06387628
What this trial is testing

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Fudan University 74
Early research (Phase 1)Looking for participantsNCT07545122
What this trial is testing

A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

Who this might be right for
Triple Negative Breast Cancer (TNBC)Colorectal CancerUrothelial Cancer
Context Therapeutics Inc. 162
Early research (Phase 1)Ended earlyNCT05274451
What this trial is testing

Investigate LYL797 in Adults With Solid Tumors

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung Cancer+20 more
Lyell Immunopharma, Inc. 57
Early research (Phase 1)Study completedNCT02014337
What this trial is testing

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Who this might be right for
Breast CancerOvarian Epithelial Cancer RecurrentSarcoma+4 more
Corcept Therapeutics 37
Next Page